https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7958 Sat 24 Mar 2018 08:34:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:995 Sat 24 Mar 2018 08:29:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11117 20 months; 5 (63%) remained alive. Clinical benefit rate (overall response + stable disease) was 21% (16 partial responses and 35 stable disease), and median overall survival was 10.0 months. Progression-free survival at 6 months was 15%, and survival was 40.3% at 12 months and 22% at 24 months. Common treatment-related adverse events were generally mild to moderate, and grade 3/4 adverse events included diarrhea (n = 28, 11%), fatigue (n = 6, 2%), and colitis (n = 9, 4%). There were 2 (0.8%) treatment-related deaths. Conclusions: Tremelimumab showed an objective response rate of 6.6%, with all responses being durable ≥170 days since enrollment, suggesting a potential role for tremelimumab in melanoma.]]> Sat 24 Mar 2018 08:09:51 AEDT ]]>